Name | Number of supported studies | Average coverage | |
---|---|---|---|
mast cell | 8 studies | 41% ± 10% | |
ciliated cell | 5 studies | 22% ± 3% | |
hepatocyte | 3 studies | 44% ± 24% |
Insufficient scRNA-seq data for expression of PZP at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 4193.48 | 226 / 226 | 20% | 2.41 | 81 / 406 |
lung | 100% | 358.68 | 578 / 578 | 13% | 0.64 | 154 / 1155 |
bladder | 100% | 72.90 | 21 / 21 | 7% | 0.37 | 34 / 504 |
breast | 98% | 110.73 | 452 / 459 | 3% | 1.06 | 33 / 1118 |
spleen | 100% | 212.48 | 241 / 241 | 0% | 0 | 0 / 0 |
uterus | 97% | 94.54 | 165 / 170 | 2% | 0.09 | 11 / 459 |
adipose | 99% | 114.45 | 1192 / 1204 | 0% | 0 | 0 / 0 |
heart | 98% | 85.55 | 843 / 861 | 0% | 0 | 0 / 0 |
thymus | 94% | 53.37 | 614 / 653 | 0% | 0 | 0 / 605 |
kidney | 90% | 47.70 | 80 / 89 | 2% | 0.09 | 20 / 901 |
prostate | 89% | 50.47 | 219 / 245 | 2% | 0.08 | 8 / 502 |
muscle | 89% | 41.53 | 718 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 86% | 39.07 | 1153 / 1335 | 0% | 0 | 0 / 0 |
esophagus | 80% | 54.22 | 1162 / 1445 | 2% | 0.03 | 3 / 183 |
brain | 80% | 110.42 | 2116 / 2642 | 1% | 0.02 | 6 / 705 |
intestine | 79% | 37.66 | 761 / 966 | 1% | 0.04 | 7 / 527 |
adrenal gland | 76% | 33.09 | 195 / 258 | 1% | 0.24 | 2 / 230 |
ovary | 68% | 26.27 | 123 / 180 | 1% | 0.02 | 6 / 430 |
stomach | 65% | 24.82 | 232 / 359 | 1% | 0.04 | 4 / 286 |
skin | 42% | 14.82 | 752 / 1809 | 1% | 0.04 | 6 / 472 |
peripheral blood | 23% | 9.33 | 217 / 929 | 0% | 0 | 0 / 0 |
pancreas | 19% | 4.99 | 62 / 328 | 2% | 0.70 | 3 / 178 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007565 | Biological process | female pregnancy |
GO_0005615 | Cellular component | extracellular space |
GO_0072562 | Cellular component | blood microparticle |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0002020 | Molecular function | protease binding |
GO_0004866 | Molecular function | endopeptidase inhibitor activity |
GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
Gene name | PZP |
Protein name | Pregnancy zone protein (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 6) Alternative protein PZP PZP alpha-2-macroglobulin like |
Synonyms | CPAMD6 |
Description | FUNCTION: Is able to inhibit all four classes of proteinases by a unique 'trapping' mechanism. This protein has a peptide stretch, called the 'bait region' which contains specific cleavage sites for different proteinases. When a proteinase cleaves the bait region, a conformational change is induced in the protein which traps the proteinase. The entrapped enzyme remains active against low molecular weight substrates (activity against high molecular weight substrates is greatly reduced). Following cleavage in the bait region a thioester bond is hydrolyzed and mediates the covalent binding of the protein to the proteinase. |
Accessions | P20742 ENST00000261336.7 [P20742-1] F5GXY0 L8EC98 ENST00000535230.5 |